V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160003623 | 160013752 | 1.7 | 74.9 | Palliative (P) | 2018-12-12 | 2019-01-03 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | N | EW EUROEWING 2012 ARM B IE | 100312421 |
| 160003704 | 160013753 | 1.8 | 73.2 | Palliative (P) | 2016-09-29 | 2016-09-30 | null | 02 | N | ICE | 101329324 |
| 160003966 | 160013755 | 1.58 | 36.5 | null | 2018-02-13 | 2018-03-08 | null | 02 | null | DACTINOMYCIN + DOXORUBICIN + IFOSFAMIDE + VINCRISTINE | 100428369 |
| 160004368 | 160013757 | 0 | 75 | Neo-adjuvant (N) | 2019-09-07 | 2019-10-23 | Trial Unspecified | 02 | N | IFOSFAMIDE | 100394972 |
| 160004387 | 160013758 | 1.6 | 12.85 | Curative (C) | 2018-02-26 | 2018-03-17 | Cyclophosphamide PO +Vinorelbine IV | 02 | null | BORTEZOMIB + DARATUMUMAB | 101203891 |
| 160004681 | 160013759 | 0 | 120 | null | 2018-07-13 | 2018-08-04 | NB Rel CCLG guidelines Cyclo-Topotecan | 02 | null | STS RHABDO RMS 2005 VIN CYCLO | 100946623 |
| 160005199 | 160013760 | 1.65 | 16.85 | Curative (C) | 2018-10-18 | 2019-09-01 | EW EuroEwing 2012 Arm A VAI | 02 | N | OLARATUMAB | 100797738 |
| 160005569 | 160013761 | 1.7 | 83.1 | Neo-adjuvant (N) | 2019-09-29 | 2019-10-28 | Palbociclib | 02 | null | CARBOPLATIN + ETOPOSIDE | 100624484 |
| 160005787 | 160013762 | 1.72 | 63.9 | null | 2019-05-19 | 2019-05-19 | NB Low/Interm risk guidelines Carbo/Etop | 02 | null | IFOSFAMIDE | 101316980 |
| 160005796 | 160013763 | 0.93 | 80 | Curative (C) | 2016-05-13 | 2016-05-14 | IVA | 02 | N | PEMBROLIZUMAB | 100762970 |
| 160005816 | 160013764 | null | 65 | Disease modification (D) | 2019-02-25 | 2019-03-20 | Cisplatin + Etoposide (3 day) | 01 | N | GEMCITABINE + TREOSULFAN | 101864654 |
| 160006388 | 160013765 | 0.99 | 72.4 | null | 2016-06-24 | 2016-09-29 | VINCRISTINE | 2 | null | CYCLOPHOSPHAMIDE + TOPOTECAN | 101297123 |
| 160006389 | 160013766 | 1.71 | 79.05 | Curative (C) | 2018-12-24 | 2020-02-23 | CYCLOPHOSPHAMIDE + VINORELBINE | 02 | null | ETOP 13-18 BEAT-MESO TRIAL | 100953709 |
| 160006523 | 160013767 | 1.8 | 55.1 | Palliative (P) | 2019-06-22 | 2019-06-26 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | N | CYCLOPHOSPHAMIDE | 100074533 |
| 160006529 | 160013768 | 0 | 78.5 | 03 | 2020-06-15 | 2020-09-16 | NB HRNBL-1 COJEC Ind COURSE C | 02 | null | DOXORUBICIN + IFOSFAMIDE | 101225141 |
| 160006838 | 160013770 | 0 | 16.5 | null | 2018-06-27 | 2019-05-12 | Rituximab | null | null | NIRAPARIB | 100170724 |
| 160006918 | 160013771 | null | 17.1 | Palliative (P) | 2019-12-16 | 2020-02-19 | ATOMIC-MESO TRIAL | 01 | null | CISPLATIN + DOXORUBICIN | 100003836 |
| 160007240 | 160013772 | 0 | 75 | 02 | 2016-08-29 | 2017-03-21 | Pemetrexed | N | N | IRINOTECAN + TEMOZOLOMIDE + VINCRISTINE | 101524382 |
| 160007389 | 160013773 | 1.78 | 0 | Palliative (P) | 2016-10-14 | 2016-12-08 | Dacarbazine | 2 | N | ETOP 13-18 BEAT-MESO TRIAL | 100844374 |
| 160007904 | 160013774 | 1.66 | 46.4 | Curative (C) | 2018-07-04 | 2018-07-25 | Ifosfamide | 02 | N | NEMO TRIAL | 100242429 |
| 160008367 | 160013775 | 1.66 | 88.2 | null | 2017-10-16 | 2017-10-17 | ATOMIC-MESO TRIAL | null | null | ETOPOSIDE + IFOSFAMIDE | 101230002 |
| 160008433 | 160013776 | 1.81 | 79.3 | null | null | 2019-08-10 | PEMBROLIZUMAB | 02 | null | IRINOTECAN + CISPLATIN + MITOMYCIN | 100659790 |
| 160008630 | 160013777 | null | 73.2 | Curative (C) | null | 2022-01-11 | EW EuroEwing 2012 Arm B VDC/IE | 02 | N | CYCLOPHOSPHAMIDE + TOPOTECAN | 100288187 |
| 160008800 | 160013778 | 0 | 68.8 | Curative (C) | 2017-09-17 | 2017-10-01 | STS Rhabdo RMS 2005 Vin Cyclo | 02 | N | IPILIMUMAB + NIVOLUMAB | 100275941 |
| 160008830 | 160013779 | 1.76 | 81.8 | null | 2020-01-17 | 2020-01-17 | Olaparib | 02 | null | IFOSFAMIDE | 100249825 |
| 160008933 | 160013780 | 1.84 | 97.1 | Palliative (P) | 2017-03-21 | 2017-04-18 | Cisplatin + Etoposide (3 day) | 02 | N | ETOPOSIDE | 101078869 |
| 160008964 | 160013781 | 1.8 | 0 | Curative (C) | 2019-07-14 | 2019-07-30 | Niraparib | 2 | Y | NB LOW/INTERMED RISK GUIDELINES CADO | 101078776 |
| 160009077 | 160013782 | 1.69 | 63.7 | Curative (C) | 2018-08-09 | 2018-10-03 | NB BEACON Temozolomide Topotecan | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101445199 |
| 160009157 | 160013783 | 1.55 | null | Curative (C) | 2017-12-26 | 2018-03-28 | STS Rhabdo RMS 2005 Vin Cyclo | N | N | STS RHABDO RMS 2005 VIN CYCLO | 101445300 |
| 160009384 | 160013784 | 1.66 | 92 | null | null | 2020-02-04 | Cyclophosphamide + Vincristine | 02 | null | NOT MATCHED | 101177507 |
| 160009395 | 160013785 | 1.54 | 75.1 | null | 2018-09-07 | 2019-07-14 | Ifosfamide | 01 | null | EW EUROEWING 2012 ARM A/B ZOL ACID | 100169012 |
| 160009476 | 160013786 | 0 | 80.15 | null | 2018-12-18 | 2018-12-30 | NB Rel CCLG guidelines Irin & Temoz | 02 | null | IFOSFAMIDE | 100784347 |
| 160009642 | 160013788 | 1.69 | 67.6 | Palliative (P) | 2019-12-18 | 2020-02-28 | Rucaparib | 01 | N | PROMISE-MESO TRIAL | 100550420 |
| 160009659 | 160013789 | 1.57 | 16 | null | 2016-09-18 | 2016-09-19 | Ifosfamide 3g/m2 5 day | 02 | null | CISPLATIN + DOXORUBICIN | 100847086 |
| 160009742 | 160013790 | 1.72 | 83.4 | Palliative (P) | 2018-02-04 | 2018-02-05 | Cisplatin + Etoposide (3 day) | 02 | null | GEMCITABINE | 101683016 |
| 160009800 | 160013791 | 1.68 | 71 | null | 2016-03-11 | 2016-04-19 | CISPLATIN + GEMCITABINE | 02 | null | NB HRNBL-1 CH14.18/CHO ONLY (TRIAL) | 100706611 |
| 160010151 | 160013793 | 1.82 | 70.6 | null | 2018-05-29 | 2018-06-22 | Etoposide oral | 02 | null | CISPLATIN + ETOPOSIDE | 100237670 |
| 160010269 | 160013795 | 1.85 | 73.3 | Palliative (P) | 2019-03-21 | 2019-04-10 | ETOPOSIDE | 02 | N | NB BEACON TEMOZOLOMIDE AND IRINOTECAN | 100684796 |
| 160010360 | 160013796 | 9.99 | 76.5 | null | 2016-08-06 | 2016-12-29 | Ifosfamide | 02 | null | GEMCITABINE | 100726315 |
| 160010408 | 160013797 | 1.57 | 15.4 | null | 2017-07-09 | 2017-07-19 | DICE TRIAL | 02 | null | DOXORUBICIN EMBOLISATION | 101861151 |
| 160010475 | 160013798 | 1.78 | 57.7 | Palliative (P) | 2018-12-10 | 2018-12-16 | VAC | 02 | N | DACARBAZINE + GEMCITABINE | 100519514 |
| 160010514 | 160013799 | 0 | 86 | null | 2018-06-27 | 2018-07-10 | Ifosfamide | 02 | null | PEMETREXED | 100292842 |
| 160010558 | 160013800 | 1.86 | 87.35 | Palliative (P) | 2019-12-26 | 2020-01-13 | Carboplatin + Vinorelbine Oral | 02 | N | BEVACIZUMAB + CARBOPLATIN + PACLITAXEL | 100888364 |
| 160010801 | 160013802 | 0 | 120 | null | 2016-10-02 | 2016-10-02 | STS Rhabdomyosarcoma RMS 2005 IVA | 02 | null | DACARBAZINE + GEMCITABINE | 100508709 |
| 160010902 | 160013804 | 1.8 | 65 | Curative (C) | 2019-09-29 | 2019-10-01 | NB HRNBL-1 BUMEL MAT | 02 | N | ETOP 13-18 BEAT-MESO TRIAL | 101515224 |
| 160010938 | 160013805 | 1.71 | 84.4 | null | 2019-04-24 | 2019-04-30 | Lenalidomide 25mg (Cycle 1 to 25) | 01 | null | CISPLATIN + DOXORUBICIN + METHOTREXATE | 101163903 |
| 160011166 | 160013806 | 1.5 | 55.2 | Curative (C) | null | 2019-05-29 | STS Rhabdo VIT0910 Vinc Irino Temoz | 02 | N | NOT MATCHED | 101542759 |
| 160011170 | 160013807 | 1.67 | 51.4 | Palliative (P) | 2019-12-21 | 2020-01-06 | ABEMACICLIB + FULVESTRANT | 02 | null | LANREOTIDE | 100199392 |
| 160011313 | 160013808 | 1.63 | 55 | 03 | 2018-09-27 | 2018-09-27 | CYCLOPHOSPHAMIDE | 02 | N | IVA | 100079327 |
| 160011320 | 160013809 | 1.83 | 0 | null | 2017-09-23 | 2017-10-18 | Niraparib | null | null | GEMCITABINE | 101746287 |